An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s disease

AIMS: Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease-modifying therapeutic for Huntington's disease (HD). This was the first study of selisistat in HD patients and was primarily aimed at development of pharmacodynamic biomarkers. METHODS: This was a randomiz...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Br J Clin Pharmacol
المؤلفون الرئيسيون: Süssmuth, Sigurd D, Haider, Salman, Landwehrmeyer, G Bernhard, Farmer, Ruth, Frost, Chris, Tripepi, Giovanna, Andersen, Claus A, Di Bacco, Marco, Lamanna, Claudia, Diodato, Enrica, Massai, Luisa, Diamanti, Daniela, Mori, Elisa, Magnoni, Letizia, Dreyhaupt, Jens, Schiefele, Karin, Craufurd, David, Saft, Carsten, Rudzinska, Monika, Ryglewicz, Danuta, Orth, Michael, Brzozy, Sebastian, Baran, Anna, Pollio, Giuseppe, Andre, Ralph, Tabrizi, Sarah J, Darpo, Borje, Westerberg, Goran
التنسيق: Artigo
اللغة:Inglês
منشور في: BlackWell Publishing Ltd 2015
الموضوعات:
Clinical Trials
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4345957/
https://ncbi.nlm.nih.gov/pubmed/25223731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12512
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة